<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682511</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-IFE-004</org_study_id>
    <nct_id>NCT02682511</nct_id>
  </id_info>
  <brief_title>Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study&#xD;
      is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic&#xD;
      SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, placebo-controlled, double-blind phase 2 trial of patients with&#xD;
      dcSSc or SSc-PAH. Twenty participants with SSc-PAH and 14 participants with dcSSc will be&#xD;
      randomized to receive either oral ifetroban daily or matching placebo. Study participants&#xD;
      will be treated for 12 months, followed by a 30-day follow-up period. The study will test&#xD;
      whether ifetroban is safe and statistically superior to placebo in reducing the effects of&#xD;
      their disease at month 12 and explore the ability of ifetroban to prevent or reverse&#xD;
      progression in patients with early disease duration and reverse established disease in&#xD;
      patients with longer disease duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>56 weeks</time_frame>
    <description>Safety is measured using AEs, including clinical significant changes in vital signs, laboratory test abnormalities and clinical tolerability of ifetroban.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in forced vital capacity (FVC)</measure>
    <time_frame>Baseline, 12, 26, and 52 weeks</time_frame>
    <description>To determine if ifetroban improves pulmonary function in subjects with diffuse cutaneous SSc or SSc-PAH compared to placebo as measured by a change from baseline FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diffusion capacity for carbon monoxide (DLCO)</measure>
    <time_frame>Baseline, 12, 26, and 52 weeks</time_frame>
    <description>To determine if ifetroban improves pulmonary function in subjects with diffuse cutaneous SSc or SSc-PAH compared to placebo as measured by a change from baseline diffusion capacity for carbon monoxide (DLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the modified Rodnan skin score (mRSS)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
    <description>The efficacy of treatment on skin fibrosis will be measured by changes from baseline in mRSS, a measure of skin thickness, at 52 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in ventricular function as determined by cardiac MRI</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in ventricular function as determined by echocardiography</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improve skin and peripheral vascular disease as measured by active digital ulcer count</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improve skin and peripheral vascular disease as measured by the subject's self-assessment of pain in digits by a visual analog scale (VAS), if active digital ulcers are present.</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in blood biomarkers</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in skin biomarkers</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in erythrocyte sedimentation rate</measure>
    <time_frame>Baseline, 26, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject-reported health status assessed by the Scleroderma Health Assessment Questionnaire (SHAQ)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject health and disability measurements as assessed by the World Health Organization Disability Assessment Assessment Schedule 2.0 (WHODAS 2.0)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject-reported gastro-intestinal tract symptoms as assessed by the University of California, Los Angles (UCLA) Scleroderma Clinical Trial Consortium (SCTC) Gastrointestinal Tract (GIT) Questionnaire</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in subject-reported outcomes as assessed by the short-form health survey (SF-36)</measure>
    <time_frame>Baseline, 12, 26, 39, and 52 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Scleroderma, Diffuse</condition>
  <condition>Scleroderma, Systemic</condition>
  <condition>Scleroderma, Limited</condition>
  <condition>Sclerosis, Progressive Systemic</condition>
  <condition>Skin Diseases</condition>
  <condition>Connective Tissue Diseases</condition>
  <condition>Pathologic Processes</condition>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Patients with dcSSc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with SSc-PAH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Ifetroban</intervention_name>
    <description>Subjects will be treated with oral ifetroban or placebo daily for 365 days</description>
    <arm_group_label>Patients with SSc-PAH</arm_group_label>
    <arm_group_label>Patients with dcSSc</arm_group_label>
    <other_name>Ifetroban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>Subjects will be treated with oral ifetroban or placebo daily for 365 days</description>
    <arm_group_label>Patients with SSc-PAH</arm_group_label>
    <arm_group_label>Patients with dcSSc</arm_group_label>
    <other_name>Ifetroban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diffuse Cutaneous Criterion:&#xD;
&#xD;
        1. Systematic Sclerosis (SSc), as defined using the 2013 American College of Rheumatology/&#xD;
        European Union League Against Rheumatism Classification Criteria and dcSSc within 7 years&#xD;
        following initial diagnosis as defined by the onset of the first non-Raynaud symptom.&#xD;
&#xD;
        SSc-PAH Criteria:&#xD;
&#xD;
          1. Adults fulfilling the 2013 American College of Rheumatology/ European Union League&#xD;
             Against Rheumatism Classification Criteria with confirmed SSc-PAH (limited or dcSSc)&#xD;
             confirmed via previous cardiac catheterization&#xD;
&#xD;
          2. Stable oral therapy for PAH for at least 30 days (monotherapy or combination)&#xD;
&#xD;
          3. New York Heart Association (NYHA) Class I-III Heart Failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a diagnosis of systemic sclerosis sine scleroderma;&#xD;
&#xD;
          2. Be less than 18 years of age or greater than or equal to 80 years of age;&#xD;
&#xD;
          3. Be pregnant, nursing, or planning to become pregnant;&#xD;
&#xD;
          4. Current or planned treatment with prostanoid therapy;&#xD;
&#xD;
          5. Current or planned treatment with pirfenidone;&#xD;
&#xD;
          6. Use of rituximab in the last 3 months;&#xD;
&#xD;
          7. Use of mycophenolic acid (Myfortic, CellCept) at a stable dose for less than 3 months;&#xD;
&#xD;
          8. Current or planned corticosteroid therapy greater than 15mg per day of prednisone or&#xD;
             prednisone equivalent;&#xD;
&#xD;
          9. Significant lung disease, defined as FVC &lt; 50% predicted or DLCO &lt;40% predicted;&#xD;
&#xD;
         10. Significant kidney disease, defined as Glomerular Filtration Rate (GFR) &lt; 60 ml/min;&#xD;
&#xD;
         11. Have moderate or severe hepatic impairment;&#xD;
&#xD;
         12. Contraindication to MRI (e.g., implanted magnetic material, claustrophobia);&#xD;
&#xD;
         13. Known hypersensitivity to gadolinium;&#xD;
&#xD;
         14. Any cause of pulmonary hypertension other than World Health Organization (WHO) Group I&#xD;
             associated with SSc;&#xD;
&#xD;
         15. Use of aspirin &gt; 81 mg per day in the last two weeks;&#xD;
&#xD;
         16. Use of warfarin, heparin or other anticoagulants in the last 30 days;&#xD;
&#xD;
         17. Recent (within 6 weeks) myocardial infarction or persistent atrial arrhythmias;&#xD;
&#xD;
         18. Have a history of allergy or hypersensitivity to ifetroban;&#xD;
&#xD;
         19. Have taken investigational drugs within 30 days before study treatment administration;&#xD;
&#xD;
         20. Inability to understand the requirements of the study, inability to understand spoken&#xD;
             English and abide by the study restrictions and to return for the required treatments&#xD;
             and assessments;&#xD;
&#xD;
         21. Be otherwise unsuitable for the study, in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Brittain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byron Kaelin, RN, BSHS</last_name>
    <phone>615-255-0068</phone>
    <phone_ext>250</phone_ext>
    <email>bkaelin@cumberlandpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jerry Fox, DVM</last_name>
    <phone>615-255-0068</phone>
    <phone_ext>226</phone_ext>
    <email>jfox@cumberlandpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Universtity of Arizona Arthrtis Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jazmin Dagnino</last_name>
      <email>jazmindagnino@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Jawad Bilal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashla Barroso</last_name>
      <phone>310-825-9682</phone>
    </contact>
    <investigator>
      <last_name>Suzanne Kafaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Life Medical Research Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Briceno, MD</last_name>
      <email>BRICENM@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Lilian Cadet</last_name>
      <email>CADETL@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Franck Rahaghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Leatherman, RN, MS, CCRP</last_name>
      <phone>410-550-8582</phone>
    </contact>
    <investigator>
      <last_name>Laura Hummer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Frenandez</last_name>
      <phone>617-724-2792</phone>
    </contact>
    <investigator>
      <last_name>Flavia Castelino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beemnet Amdemicael</last_name>
      <phone>212-774-2123</phone>
    </contact>
    <investigator>
      <last_name>Jessica Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Simmons</last_name>
      <email>Marsha.Simmons@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Fabian A Mendoza-Ballesteros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204-651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan</last_name>
    </contact>
    <investigator>
      <last_name>Susan Mathai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaraoya Research Institute at Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>KDH - Kokilaben Dhirubhai Ambani Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gauri Pandit, MBBS</last_name>
      <email>Gauri.Pandit@relianceada.com</email>
    </contact>
    <contact_backup>
      <last_name>Sanchita Gupte, MBBS</last_name>
      <email>sanchita.gupte@relianceada.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sunil Singh, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>B. J. Government Medical College</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijaya Chavan</last_name>
      <email>orion.vijayachavan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Arohi Metkar</last_name>
      <email>Orion.arohi@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shefali Khanna, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Shashank Gaur</last_name>
      <email>ethicscare@ecrsindia.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ifetroban</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Systemic Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
    <mesh_term>Scleroderma, Limited</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifetroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

